Advanced research on neoadjuvant therapy with trastuzumab in HER2-positive breast cancer
10.3969/j.issn.1000-8179.20132207
- VernacularTitle:曲妥珠单抗在HER-2阳性乳腺癌患者新辅助治疗中的应用研究进展
- Author:
Jun LIU
;
Yanfang YANG
;
Lin GU
- Publication Type:Journal Article
- Keywords:
trastuzumab;
neo-adjuvant therapy;
HER-2;
breast cancer
- From:
Chinese Journal of Clinical Oncology
2014;(16):1065-1068
- CountryChina
- Language:Chinese
-
Abstract:
Trastuzumab is a specific inhibitor against human epidermal growth factor receptor-2 (HER-2). Trastuzumab is widely used in the neo-adjuvant treatment of HER-2 breast cancer. Large-scale randomized and controlled clinical trials have demonstrated that pathologic complete response rates (pCRs) were significantly increased with neo-adjuvant trastuzumab therapy plus chemotherapy than with regular chemotherapy. The use of trastuzumab plus chemotherapy with lapatinib supplements could further improve pCR rates. An-thracycline and non-anthracycline drugs could both be used concurrently with trastuzumab. Endocrine therapy could be used as an alter-native for estrogen receptor-positive patients. pCR is a powerful predictor of long-term outcomes in HER-2 positive patients under neo-adjuvant therapy with trastuzumab. However, patient loss of HER-2 expression with residual disease after neo-adjuvant therapy with trastuzumab is a poor prognostic factor. This study paper will provide a review of related research.
